The FDA Has Warned 55 Telehealth Companies This Year. What It Means If You Buy Hormones Online

If you buy hormones or weight-loss medication from a telehealth company, something has been happening in the background this year that is worth ten minutes of your attention.

During the week of 15 June 2026, the FDA issued 25 warning letters to telehealth companies over allegedly false or misleading promotional claims about compounded medications. That followed 30 warning letters on 3 March, and an earlier round in September 2025 aimed at the compounding pharmacies themselves. The agency's position is that the marketing misbrands the products under the Federal Food, Drug and Cosmetic Act.

This is not a fringe enforcement action against back-alley operators. These are consumer-facing brands with polished websites, the kind that appear in search results and social feeds alongside the ones we cover.

What the FDA actually objected to

The letters are not about the medications being dangerous. They are about how they were sold. Three patterns come up repeatedly:

• Implying compounded products are equivalent to FDA-approved ones. They are not. A compounded preparation is mixed by a pharmacy for an individual patient and has not been reviewed by the FDA for safety, effectiveness or manufacturing quality.
• Using "FDA-approved" language about sourcing. Saying the active ingredient comes from an FDA-registered facility is true but tells you nothing about the finished product. Marketing that lets a reader hear "this medication is FDA-approved" from that phrasing is the exact problem being cited.
• Branding that obscures who actually compounds the drug. If you cannot tell which pharmacy made what you are putting in your body, that is by design rather than accident.

Notice the through-line. Every one of these is about a company being vague on the single question that matters most: is this an FDA-approved product or not?

The disclosure we owe you

Two things about our own position, because this article would be worthless without them.

One company listed in our provider directory was named in the June letters: Thrivelab. We have added a note to its listing. A warning letter is an allegation and an opportunity to respond, not a final determination of wrongdoing, and we are not suggesting otherwise. But it is material information for anyone weighing that provider, and it should not take a reader digging through FDA press releases to find it.

We earn commission from several telehealth companies, and some of them sell compounded products. Gala Health's hormones are compounded, which its landing page states in the fine print. The GLP-1 partners we link to sell compounded semaglutide and tirzepatide. None of our tracked partners appeared in the March or June letters, and we checked the published lists specifically to be able to tell you that. But we are not a neutral observer here, and you should read the rest of this with that in mind.

Why this matters more for menopause than it looks

The June letters concerned compounded GLP-1 marketing rather than hormone therapy. But the underlying issue applies directly to menopause care, because most online menopause platforms dispense compounded hormones, and the same vagueness is common.

The professional guidance here is not ambiguous. ACOG's clinical consensus on compounded bioidentical menopausal hormone therapy, and the National Academies review before it, both land in the same place: compounded hormone therapy should generally be reserved for patients who cannot use an FDA-approved product. An allergy to an excipient, a dose that is not commercially manufactured, or a form that does not exist commercially are all legitimate reasons. "It is more natural" and "it is personalised to your levels" are not.

That matters because FDA-approved bioidentical hormones exist. Estradiol patches, tablets, gels and sprays, and micronized progesterone capsules are all approved products containing the same molecules your body makes. The word "bioidentical" describes chemistry, not regulatory status, and marketing has attached it almost exclusively to compounded products in a way that implies the approved ones are somehow synthetic. They are not.

The context that makes this confusing

All of this is happening at the same time as the opposite kind of news. In February 2026 the FDA removed the boxed warning from menopausal hormone therapy products, after concluding the previous language overstated risk for most women starting treatment before 60 or within ten years of menopause. Prescriptions rose sharply afterwards.

So the headlines this year have run in two directions at once: hormone therapy itself has been formally reassessed as safer than the old labelling implied, while the FDA has simultaneously escalated action against how some telehealth companies market compounded versions of it.

Those are not contradictory. One is about the treatment. The other is about the sales pitch. Hormone therapy being more favourably assessed does not make every company selling it trustworthy, and that gap is precisely where a reader can get hurt.

Three questions that protect you

You do not need to follow FDA enforcement to stay out of trouble. Ask these before you pay.

1. "Is the specific product you would prescribe me FDA-approved, or compounded?" Ask for the answer in writing. A straight answer is a good sign regardless of which one it is. Evasion, or a pivot to talking about ingredient sourcing, is the pattern the FDA has been writing letters about.

2. "If it is compounded, what is the clinical reason in my case?" There are real reasons. A provider who has one will say it plainly. A provider who tells you compounded is inherently safer or more natural has told you how they practise.

3. "Which pharmacy dispenses it?" You are entitled to know. If the answer is unclear, that is the third pattern from the warning letters showing up in your own transaction.

What not to conclude

Do not read this as "compounded means unsafe". It does not. Compounding is a legitimate, regulated practice that solves real clinical problems, and millions of prescriptions are filled that way without incident.

Do not read it as "telehealth is a scam" either. For a great many women, telehealth is the only route to a clinician who actually treats menopause, and the alternative is not better care but no care.

The correct conclusion is narrower and more useful: a company that will not tell you plainly what it is selling you has given you the information you needed. That was true before these letters and it will be true after them.

If you want to go further, our guide on compounded versus FDA-approved hormones explains when each is the right call, our 9-point check for telling a legitimate online HRT service from a risky one covers how to verify a platform and its pharmacy yourself in about five minutes, and our ranked comparison of online HRT providers lists hormone sourcing alongside price and state coverage.